Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

Also called NCT01194258

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
Halozyme Therapeutics (from the registry)
Registry
  • NCT NCT01194258
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01194258. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2014-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type II
Intervention (Drug)
Insulin lispro
Intervention (Drug)
Insulin aspart
Intervention (Drug)
Recombinant human hyaluronidase PH20
Intervention (Drug)
Insulin glulisine
Intervention (Drug)
Insulin glargine
Lead sponsor
Halozyme Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01194258
Content hash
af7c2e184f1447daf230844fd78c69e9594ccca3df05db72dc315443049cef72